Indoco Remedies shares surge 16% after UKMHRA inspects Goa plant

Indoco Remedies Ltd saw its shares climb roughly 16% in recent trading after the United Kingdom's Medicines and Healthcare products Regulatory Agency completed an inspection of the company's manufacturing facility in Goa. The regulatory visit, which evaluates compliance with international Good Manufacturing Practices, concluded without any publicly disclosed adverse findings, prompting investors to view the outcome favorably. Market analysts said the positive regulatory signal could enhance the company's export prospects, especially to the UK market, and strengthen its position in the competitive generic drug sector. The share rally reflects renewed confidence that Indoco can meet stringent overseas quality standards, a critical factor for Indian pharmaceutical exporters.